Tesla, Inc. vs Twist Bioscience Corp — how do they compare? Tesla, Inc. trades at $379.19 (market cap $1.39T), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Tesla, Inc. is far larger — about 255× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| TSLA | TWST | |
|---|---|---|
Market Cap | $1.39T | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $102.88 |
52-Week Low | $302.63 | $24.16 |
Enterprise Value | $1.36T | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $378.88, down 0.51% with a bearish technical outlook. The stock faces valuation concerns with a P/E of 339 and declining profitability margins, though recent earnings beat expectations. Cash flow remains positive despite heavy capital investments. European regulatory approval for driver-assistance software and German sales growth provide optimism, but competition and slowing auto business present challenges.
Tesla's outlook balances innovation potential against execution risks. The stock offers growth exposure to AI and autonomy but carries premium valuation and competitive pressures. Near-term catalysts include Q2 earnings and robotaxi developments, while margin compression and market sentiment shifts represent key investor risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →